Quantcast
Last updated on April 24, 2014 at 13:57 EDT

Latest Cetuximab Stories

2012-10-21 19:20:07

MAGDEBURG, Germany, October 21, 2012 /PRNewswire/ -- Survival of patients treated with SIR-Spheres more than double that of patients who received best supportive care, benefit rivals that found with new biological agents, authors note The results of a matched-pair comparison of patients with metastatic colorectal cancer predominately affecting the liver, for whom all chemotherapy options had been exhausted, showed that the addition of radioembolization using SIR-Spheres...

2012-10-01 22:20:55

SEATTLE, Oct. 2, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced that OPAXIO (paclitaxel poliglumex) has been granted orphan-drug designation by the U.S Food and Drug Administration ("FDA") for the treatment of glioblastoma multiforme ("GBM"), a malignant brain cancer. Orphan designation was granted based on preliminary activity seen from phase 2 results of OPAXIO when added to standard therapy (temozolamide ("TMZ") plus radiation). In this study,...

2012-09-27 06:28:54

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., Sept. 27, 2012 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the U.S. Food and Drug Administration (FDA) approved Bayer's Stivarga(®) (regorafenib) tablets for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with currently available therapies (including fluoropyrimidine-, oxaliplatin- and irinotecan-based...

2012-09-09 23:01:40

The Oncology Institute of Hope and Innovation is proud to have access to the latest research, technology and treatment options, including clinical trials for eligible patients with colorectal cancer. Downey, California (PRWEB) September 09, 2012 The Oncology Institute of Hope and Innovation is proud to have access to the latest research, technology and treatment options, including clinical trials for eligible patients. We are dedicated to providing comprehensive medical services to our...

2012-09-05 22:22:16

COPENHAGEN, Denmark, September 6, 2012 /PRNewswire/ -- - Symphogen Will Host a Conference Call Today (Thursday 6 September 2012) to Discuss the Announcement at 11:30 CET/ 10:30 BST, Details on How Access This Call and the Accompanying Presentation are Below. - A novel investigational antibody mixture targeting the epidermal growth factor receptor (EGFR) Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody...

2012-09-05 02:32:26

SEATTLE, Sept. 5, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that an ongoing Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer will be expanded to include an additional group of up to 25 patients whose disease has begun to progress while receiving abiraterone (Zytiga®) and prednisone. PX-866 is Oncothyreon's small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K),...

2012-07-06 10:21:58

HILDEN, Germany, and GERMANTOWN, Maryland, July 6, 2012 /PRNewswire/ -- - U.S. launch of therascreen(R)KRAS RGQ PCR Kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer - First FDA approval of a QIAGEN companion diagnostic marks a milestone in its global expansion of rapidly growing Personalized Healthcare business - Important cancer assay adds...

2012-06-18 06:29:14

BALTIMORE, Maryland and HAMBURG, Germany, June 18, 2012 /PRNewswire/ -- Two studies published back-to-back in last week's Nature applied DNA blood testing using the BEAMing technology to detect drug resistance mediated by KRAS mutations in colorectal cancer patients months before treatment failure was observed. The group led by Alberto Bardelli, PhD of the University of Torino, Italy describes the development of secondary resistance mutations to the anti-EGFR monoclonal...

2012-06-13 14:53:48

Targeted cancer cell therapies using man-made proteins dramatically shrink many tumors in the first few months of treatment, but new research from Johns Hopkins scientists finds why the cells all too often become resistant, the treatment stops working, and the disease returns. In a study of 28 advanced colon cancer patients treated with the monoclonal antibody panitumumab, the Johns Hopkins Kimmel Cancer Center team reports that drug-resistance tumor cell mutations appear in the blood of...

2012-06-02 10:20:13

SEATTLE, June 2, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that data from two clinical trials of PX-866, a pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.  Oncothyreon also provided an update on the status of its ongoing Phase 2 development program for PX-866. Phase 1 Trial of PX-866 in Combination with Docetaxel Data from the Phase 1 portion of...